Characterization of Adult-Onset Diabetes Patients Positive in 3 Screen ICA (TM) ELISA

This abstract has open access
Abstract Summary

Background: The prevalence of diabetes associated antibodies (Ab) in Chinese patients recently diagnosed with adult-onset diabetes and the potential role of autoantibody markers for disease phenotype characterization were studied. Methods: 1383 recent-onset adult diabetic patients (mean age 54 years) were included in the study. Serum samples collected within 12 months from diagnosis were tested using 3 Screen ICA (TM) ELISA (3-Screen) designed for combined measurement of GADAb and/or IA-2Ab and/or ZnT8Ab. 3-Screen positive samples were tested for individual diabetes associated and other organ-specific autoantibodies. Clinical characteristics of patients positive and negative in 3-Screen were analysed. Results: 46/1383 (3.3%) recent-onset adult diabetic patients were positive in 3-Screen. 39/46 (85%) positive patients were positive for at least one of GADAb, IA-2Ab and ZnT8Ab in the individual assays. Furthermore, 16/46 (35%) 3 Screen positive patients were positive for at least one thyroid autoantibody (thyroid peroxidase Ab and/or thyroglobulin Ab and/or thyrotropin receptor Ab) while none for adrenal autoantibody. 17/244 (7%) patients who had ketoacidosis and 19/351 (5.4%) patients on insulin treatment were positive in 3-Screen. 950/1383 patients were classed as phenotypic type 2 diabetes and were ketosis-free and not on insulin treatment at 6 months after diagnosis. 26/950 (2.7%) patients were 3-Screen positive and these patients were leaner with lower fasting C-peptide/insulin level and higher HbA1 level compared to 924 3-Screen negative patients. In an updated homeostatic model assessment (HOMA2), HOMA2-β cell function was significantly lower (p < 0.05) for the 26 positive patients with higher insulin sensitivity and lower insulin resistance compared to negative patients. Overall, a population of diabetes autoantibody positive adult-onset diabetes patients with a characteristic phenotype was identified using 3-Screen ELISA. This may be helpful in management of different populations of patients.

Submission ID :
IDS1446
Submission Type
Abstract Topics
Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, 300070 Tianjin, China
FIRS Laboratories, RSR Ltd, Parc Ty Glas, Llanishen, Cardiff, CF14 5DU, UK
RSR Tianjin Biotech Ltd, Haitai Green Area, Hi Huayuan Industrial Park, 300384 Tianjin, China
FIRS Laboratories, RSR Ltd, Parc Ty Glas, Llanishen, Cardiff, CF14 5DU, UK & RSR Tianjin Biotech Ltd, Haitai Green Area, Hi Huayuan Industrial Park, 300384 Tianjin, China
FIRS Laboratories, RSR Ltd, Parc Ty Glas, Llanishen, Cardiff, CF14 5DU, UK
FIRS Laboratories, RSR Ltd, Parc Ty Glas, Llanishen, Cardiff, CF14 5DU, UK
FIRS Laboratories, RSR Ltd, Parc Ty Glas, Llanishen, Cardiff, CF14 5DU, UK & RSR Tianjin Biotech Ltd, Haitai Green Area, Hi Huayuan Industrial Park, 300384 Tianjin, China
Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, 300070 Tianjin, China

Abstracts With Same Type

Submission ID
Submission Title
Submission Topic
Submission Type
Primary Author
5 visits

KEY DATES

Event dates:
Thursday 25 October - Monday 29 October 2018

Abstract submission deadline:
Monday 14 May 2018

Abstract notification:
July 2018

Early registration deadline:
Monday 3 September 2018

Registration deadline:
Monday 15 October 2018

Contact
British Society for Immunology
+44 (0)20 3019 5901
congress@immunology.org